Latest News & Updates
Breaking News
1 day ago
Simantini Singh Deo
Other trending news you may like to read
AVEROA Secures UK MHRA Approval For XOANACYL®, A First-In-Class Oral Therapy Designed To Treat Major Complications Of Chronic Kidney Disease (CKD)
Averoa secures UK MHRA approval for XOANACYL, the first dual-action oral therapy treating iron deficiency and high phosphorus in CKD patients.
Simantini Singh Deo
Turn Therapeutics Strengthens Leadership Team With Appointment Of Andrew Scott As Vice President Of Corporate Communications To Drive Capital Markets And Investor Strategy
Turn Therapeutics appoints Andrew Scott as Vice President of Corporate Communications to lead investor relations, partnerships, and capital markets strategy.
Simantini Singh Deo
Normunity Doses First Patient In Phase 1 Clinical Trial Of NRM 823, A Novel T Cell Engager Targeting Tumor-Specific Antigens In Solid Tumors
Normunity begins Phase 1 clinical trial for NRM-823, a first-in-class T cell engager targeting a novel tumor-specific antigen in advanced solid tumors.
Simantini Singh Deo
Jupiter Neurosciences Receives FDA Clearance To Begin Phase 2a Clinical Trial Of JOTROL™ For The Treatment Of Parkinson’s Disease
Jupiter Neurosciences receives FDA clearance to begin a Phase 2a trial of JOTROL™ for Parkinson’s disease, advancing its resveratrol-based neuroprotective therapy.
Simantini Singh Deo
